Johnson & Johnson buy The Goldman Sachs Group, Inc.
Start price
09.04.25
/
50%
€130.32
Target price
09.04.26
€155.92
Performance (%)
58.11%
End price
10.04.26
€206.05
Summary
This prediction ended on 10.04.26 with a price of €206.05. The BUY prediction by The_Goldman_Sachs_Gr for Johnson & Johnson saw massive gains of 58.11%. The_Goldman_Sachs_Gr has a follow-up prediction for Johnson & Johnson where he still thinks Johnson & Johnson is a Buy. The_Goldman_Sachs_Gr has 50% into this predictionJohnson Johnson is a multinational company that focuses on the development, manufacturing, and marketing of a wide range of consumer health products, medical devices, and pharmaceuticals. The company was founded in 1886 and is headquartered in New Jersey, USA. It operates in more than 60 countries and has a diverse portfolio of popular brands including Band-Aid, Tylenol, and Neutrogena. As of 2021, Johnson Johnson has a market capitalization of over $435 billion and is listed on the New York Stock Exchange under the symbol JNJ.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Johnson & Johnson | -0.973% | -0.973% | 49.721% |
| iShares Core DAX® | 4.244% | 2.864% | 14.030% |
| iShares Nasdaq 100 | 4.890% | 2.814% | 32.707% |
| iShares Nikkei 225® | 9.397% | 7.826% | 48.296% |
| iShares S&P 500 | 3.528% | 1.950% | 25.247% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Johnson & Johnson diskutieren
Johnson & Johnson (NYSE: JNJ) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $172.00 price target on the stock, up previously from $157.00.
Ratings data for JNJ provided by MarketBeat
In the thread Trading Johnson & Johnson
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten